尿道感染检测市场－2026-2031年预测

预计到 2025 年，尿道感染检测市场规模将达到 723,625,000 美元，到 2031 年将达到 1,058,701,000 美元，复合年增长率为 6.55%。

尿道感染(UTI) 检测市场涵盖多种旨在检测和识别泌尿系统（包括肾臟、输尿管、膀胱和尿道）感染疾病的调查方法。检测方法从传统的尿液检查和尿液培养到先进的快速诊断检测、分子检测和照护现场(POC) 设备，种类繁多。选择合适的检测方法取决于患者的症状、病历和临床情况，始终以获得准确且快速的结果为目标，从而指导有效的抗菌治疗决策。

主要市场成长要素

市场扩张是由流行病学、人口统计和技术因素共同推动的，这些因素同时推动了检测量的增加和更复杂的诊断方法。

全球尿道感染（UTI）的高发生率及其持续成长是推动市场需求的重要因素。泌尿道感染是最常见的细菌感染疾病之一，消耗了大量的医疗资源，涵盖门诊、急诊和住院等各个环节。这种沉重的临床负担使得人们迫切需要可靠的诊断检测方法来确诊感染、指南适当的治疗，并减少併发症和復发。

泌尿道感染的高发生率，加上民众和临床医师对泌尿道感染症状及及时诊断重要性的认识不断提高，促使检测量增加。教育宣传活动和公共卫生讯息鼓励儘早医，这也促进了检测量的增加。对于医疗服务提供者而言，认识的提高凸显了准确诊断的必要性，以便将泌尿道感染与其他具有类似症状的疾病区分开来，并促进了最佳的抗生素管理。

从人口统计学角度来看，人口老化是全球一项重要的趋势，也是重要的成长要素。老年人，尤其是长期居住在护理机构的老年人，由于免疫功能老龄化增长而下降、合併糖尿病、尿失禁以及使用留置导尿管等因素，更容易发生尿路感染。此外，老年人的症状通常不典型或特异性，因此需要降低诊断检测的阈值，以避免漏诊和尿脓毒症等严重后遗症。

技术进步与市场演变

塑造市场格局的关键趋势之一是快速、高精度诊断技术的开发和广泛应用。与需要 24-48 小时的传统培养方法相比，市场明显倾向于选择能够缩短检测时间的解决方案。主要进展包括：

• 增强照护现场检测 (POC)：可在几分钟内提供结果，为基层医疗和急诊环境提供即时的临床决策支援。
• 分子诊断检测：利用 PCR 和多重检测板，我们可以在数小时内鑑定病原体，特别是重要的抗菌素抗药性标记，从而直接支持标靶治疗。
• 自动化尿液分析系统：提高常规尿液筛检的速度、一致性和定量准确性。

这些技术进步对于改善患者照护路径、儘早开始适当治疗以及支持更广泛的抗菌药物管理倡议至关重要。

主要市场挑战

尿道感染检测领域面临的一大挑战是全球抗菌素抗药性（AMR）危机，而抗生素的过度使用是造成这场危机的部分原因。目前，对于疑似尿道感染，在未确诊的情况下经验性地使用抗生素的做法仍然十分普遍，这助长了抗药性细菌的出现。这种情况对检测市场提出了双重要求：首先，提供快速且方便的诊断方法，以遏制不必要的抗生素使用；其次，研发能够准确检测抗药性病原体的检测方法，从而指导合理的治疗。因此，先进检测技术的成功与否，本质上取决于临床行为向「检测优先」模式的转变。

区域市场展望

预计北美将继续保持尿道感染检测市场的主导地位。这主要归功于该地区尿道感染报告发病率高、诊断基础设施完善、医疗保健支出巨大以及对先进检测技术的早期应用。此外，该地区人口老化严重以及法规结构健全，进一步增强了对常规和先进诊断解决方案的需求。

竞争格局与产品差异化

竞争格局包括众多大型多元化诊断和专业生命科学公司。产品开发重点在于满足关键市场需求：

• 速度和工作流程效率：我们提供一个整合系统，简化从检体到结果的测试流程，减少人工操作时间，提高检查室吞吐量。
• 全面病原体鑑定：不仅限于简单的检测，还能从单一检体中详细鑑定多种泌尿道病原体。
• 抗生素抗药性检测：整合关键抗生素抗药性标记（例如，ESBL、碳青霉烯酶基因）的检测，以直接指导治疗选择和药物管理工作。
• 照护现场近性：透过开发易于使用的、CLIA豁免的设备，在非检查室环境中提供可靠的检测结果，从而扩大检测的可近性。

总之，尿道感染检测市场正随着持续的临床需求和以诊断主导的抗生素合理使用的迫切需求而不断发展。人口结构变化和技术创新是推动市场成长的关键因素，这些创新能够提供更快、更准确的检测结果。未来，快速、多重分子诊断能否成功整合到常规诊疗流程中，将决定市场的发展方向，使临床医师能够快速、准确地做出治疗决策。这种转变不仅对改善个别患者的治疗效果至关重要，而且在全球对抗抗菌素抗药性的行动中也发挥关键作用。

本报告的主要优势：

• 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
• 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
• 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
• 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
• 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

• 历史资料（2021-2025 年）和预测资料（2026-2031 年）
• 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
• 竞争对手定位、策略和市场占有率分析
• 按业务板块和地区（国家）分類的收入成长和预测分析
• 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 分析范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策和法规
• 策略建议

第四章 技术展望

第五章 依感染类型分類的尿道感染检测市场

• 介绍
• 尿道炎
• 膀胱炎
• 肾盂肾炎

第六章 依检测类型尿道感染检测市场

• 介绍
• 尿液分析
• 尿液培养
• 其他的

第七章 依最终用户分類的尿道感染检测市场

• 介绍
• 医院
• 诊断中心
• 其他的

第八章 各地区尿道感染检测市场

• 介绍
• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章：竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 企业合併、协议、商业合作
• 竞争对手仪錶板

第十章：公司简介

• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Randox Laboratories Ltd
• Prima Lab SA
• NxGen MDx
• Acutis Diagnostics
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• bioMerieux SA
• Sysmex Corporation

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 分析方法
• 简称

Urinary Tract Infection Testing Market is anticipated to grow at a 6.55% CAGR, increasing from USD 723.625 million in 2025 to USD 1058.701 million in 2031.

The Urinary Tract Infection (UTI) testing market encompasses a range of diagnostic methodologies designed to detect and identify infections within the urinary system, including the kidneys, ureters, bladder, and urethra. Testing modalities vary from traditional urinalysis and urine culture to advanced rapid diagnostic tests, molecular assays, and point-of-care (POC) devices. The selection of an appropriate test is guided by patient symptomatology, medical history, and the clinical setting, with a constant focus on achieving accurate, timely results to inform effective antimicrobial therapy.

Primary Market Growth Drivers

Market expansion is propelled by a confluence of epidemiological, demographic, and technological factors that are increasing both the volume of testing and the sophistication of diagnostic approaches.

The high and increasing prevalence of UTIs globally is the fundamental demand driver. UTIs remain one of the most common bacterial infections, leading to significant healthcare utilization across outpatient, emergency department, and inpatient settings. This substantial clinical burden creates a continuous, high-volume need for reliable diagnostic testing to confirm infection, guide appropriate treatment, and help mitigate complications and recurrence.

Complementing this prevalence is a growing public and clinical awareness of UTI symptoms and the importance of timely diagnosis. Educational initiatives and public health messaging are encouraging individuals to seek medical evaluation earlier, which in turn drives testing volumes. For healthcare providers, heightened awareness underscores the need for accurate diagnostics to differentiate UTIs from other conditions with similar presentations, thereby optimizing antibiotic stewardship.

Demographically, the global trend of population aging is a significant growth catalyst. Older adults, particularly those in long-term care settings, exhibit increased susceptibility to UTIs due to factors such as immunosenescence, comorbid conditions (e.g., diabetes), urinary incontinence, and the use of indwelling catheters. Furthermore, presentations in the elderly can be atypical or non-specific, necessitating a lower threshold for diagnostic testing to avoid underdiagnosis and serious sequelae like urosepsis.

Technological Advancements and Market Evolution

A key trend shaping the market is the development and adoption of rapid and more precise diagnostic technologies. There is a clear shift toward solutions that reduce the time-to-result compared to standard culture methods, which can take 24-48 hours. Advancements include:

• Enhanced Point-of-Care (POC) Tests: Providing results in minutes to guide immediate clinical decisions in primary care or emergency settings.
• Molecular Diagnostic Assays: Utilizing PCR and multiplex panels to deliver pathogen identification and, critically, antimicrobial resistance markers within a few hours, directly supporting targeted therapy.
• Automated Urinalysis Systems: Improving the speed, consistency, and quantitative accuracy of routine urine screening.

These technological advancements are critical for improving patient care pathways, enabling earlier initiation of correct therapy, and supporting broader antimicrobial stewardship initiatives.

Critical Market Challenges

A major challenge confronting the UTI testing landscape is the global crisis of antimicrobial resistance (AMR), fueled in part by antibiotic overuse. Empirical prescription of antibiotics for suspected UTIs without diagnostic confirmation remains common, contributing to resistance development. This environment creates a dual imperative for the testing market: first, to provide rapid, accessible diagnostics that can curb unnecessary antibiotic use; and second, to evolve tests that can accurately detect resistant pathogens to guide appropriate therapy. The success of advanced testing is, therefore, intrinsically linked to changing clinical behavior toward a "test-first" paradigm.

Geographic Market Outlook

North America is projected to maintain a dominant position in the UTI testing market. This is attributed to the region's high reported incidence of UTIs, a well-established diagnostic infrastructure, significant healthcare expenditure, and early adoption of advanced testing technologies. The presence of a large aging population and robust regulatory frameworks further solidify demand for both routine and sophisticated diagnostic solutions in this region.

Competitive Landscape and Product Differentiation

The competitive environment includes large, diversified diagnostic corporations and specialized life science firms. Product development is focused on addressing key market needs:

• Speed and Workflow Efficiency: Offering integrated systems that streamline testing from sample to result, reducing hands-on time and improving laboratory throughput.
• Comprehensive Pathogen Identification: Moving beyond simple detection to provide detailed identification of a broad panel of uropathogens from a single sample.
• Resistance Detection: Integrating detection of key antibiotic resistance markers (e.g., ESBL, carbapenemase genes) to directly inform therapeutic choices and stewardship efforts.
• Point-of-Care Accessibility: Developing easy-to-use, CLIA-waived devices that deliver reliable results in non-laboratory settings, expanding test access.

In conclusion, the UTI testing market is evolving in response to persistent clinical demand and the urgent need for diagnostic-driven antibiotic stewardship. Growth is underpinned by demographic shifts and technological innovation aimed at delivering faster, more informative results. The market's future trajectory will be defined by the successful integration of rapid, multiplexed molecular diagnostics into routine care pathways, empowering clinicians to make precise therapeutic decisions swiftly. This shift is essential not only for improving individual patient outcomes but also for playing a critical role in the global effort to combat antimicrobial resistance.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Urinary Tract Infection Testing Market Segmentation

• By Infection Type
• Urethritis
• Cystitis
• Pyelonephritis
• By Test Type
• Urinalysis
• Urine Culture Test
• Others
• By End-User
• Hospitals
• Diagnostic Centers
• Others
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. URINARY TRACT INFECTION TESTING MARKET BY INFECTION TYPE

• 5.1. Introduction
• 5.2. Urethritis
• 5.3. Cystitis
• 5.4. Pyelonephritis

6. URINARY TRACT INFECTION TESTING MARKET BY TEST TYPE

• 6.1. Introduction
• 6.2. Urinanalysis
• 6.3. Urine Culture Test
• 6.4. Others

7. URINARY TRACT INFECTION TESTING MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Diagnostic Centers
• 7.4. Others

8. URINARY TRACT INFECTION TESTING MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Thermo Fisher Scientific Inc.
• 10.2. Danaher Corporation
• 10.3. Randox Laboratories Ltd
• 10.4. Prima Lab SA
• 10.5. NxGen MDx
• 10.6. Acutis Diagnostics
• 10.7. F. Hoffmann-La Roche Ltd.
• 10.8. Siemens Healthineers AG
• 10.9. bioMerieux SA
• 10.10. Sysmex Corporation

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations